Curative Biotechnology, Inc. (OTCPK: CUBT)
Health Care · Biotechnology · US
$1.00
+3.30% today · -32.7% 1Y
Curative Biotechnology, Inc. (OTCPK: CUBT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.15M and employs 4 people.
Over the last twelve months the share price has lost 32.7%, trading between 0.03 and 1.99.
Tweenvest scores Curative Biotechnology, Inc. across four factors: quality 14/100. Its strongest factor is quality.
CUBT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.15M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.42
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- $1.99
- 52-week low
- $0.03
- Avg volume (3M)
- —
- Shares outstanding
- 7.15M
- Employees
- 4
- Next earnings
- —
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
- ISIN
- US23128N3061
- Founded
- 1995
- Listed since
- Mar 30, 1998
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.